BR112016017597A2 - Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo - Google Patents

Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo

Info

Publication number
BR112016017597A2
BR112016017597A2 BR112016017597A BR112016017597A BR112016017597A2 BR 112016017597 A2 BR112016017597 A2 BR 112016017597A2 BR 112016017597 A BR112016017597 A BR 112016017597A BR 112016017597 A BR112016017597 A BR 112016017597A BR 112016017597 A2 BR112016017597 A2 BR 112016017597A2
Authority
BR
Brazil
Prior art keywords
cell
producing
antigen
interest
selecting
Prior art date
Application number
BR112016017597A
Other languages
English (en)
Inventor
Jeroen Kwakkenbos Mark
Wagner Koen
Quirinus Bakker Adrianus
Original Assignee
Aimm Therapeutics Bv
Kling Biotherapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv, Kling Biotherapeutics B V filed Critical Aimm Therapeutics Bv
Publication of BR112016017597A2 publication Critical patent/BR112016017597A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MÉTODOS PARA PRODUZIR UMA CÉLULA B, PARA SELECIONAR PELO MENOS UMA CÉLULA B, PARA PRODUZIR ANTICORPOS ESPECÍFICOS PARA UM ANTÍGENO DE INTERESSE E PARA IDENTIFICAR PELO MENOS UMA MUTAÇÃO NA SEQUÊNCIA DE AMINOÁCIDO DA CADEIA PESADA E/OU CADEIA LEVE DE UM ANTICORPO. A invenção provê meios e métodos para selecionar e produzir anticorpos estáveis contra um antígeno de interesse, usando culturas de célula B ex vivo estáveis.
BR112016017597A 2014-01-31 2015-01-30 Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo BR112016017597A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14153480 2014-01-31
PCT/NL2015/050054 WO2015115892A1 (en) 2014-01-31 2015-01-30 Means and methods for producing stable antibodies

Publications (1)

Publication Number Publication Date
BR112016017597A2 true BR112016017597A2 (pt) 2017-08-08

Family

ID=50031190

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017597A BR112016017597A2 (pt) 2014-01-31 2015-01-30 Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo

Country Status (8)

Country Link
US (1) US10611829B2 (pt)
EP (1) EP3099709B1 (pt)
JP (1) JP6747975B2 (pt)
AU (1) AU2015211480B2 (pt)
BR (1) BR112016017597A2 (pt)
CA (1) CA2938193C (pt)
DK (1) DK3099709T3 (pt)
WO (1) WO2015115892A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934660C (en) * 2013-12-24 2023-03-14 Aimm Therapeutics B.V. Ex vivo antibody production
KR102037183B1 (ko) * 2018-02-09 2019-10-28 엠랩 주식회사 스트리밍 미디어에 코멘트를 맵핑하는 시스템 및 방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
EP0402402B1 (en) 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
WO1994007367A1 (en) 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
WO1994008004A1 (en) 1992-10-05 1994-04-14 Hybridon, Inc. Therapeutic anti-hiv oligonucleotide and pharmaceutical
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
AU679120B2 (en) 1993-09-03 1997-06-19 Systemix, Inc. Genetically modified human hematopoietic stem cells and their progeny
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6001558A (en) 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
DE60035515T2 (de) 1999-09-08 2008-04-17 GeneTrol Biotherapeutics, Inc., Oakland Hohe zytokinproduktion mit verbesserter zelllebensfähigkeit
EP1083230A1 (en) 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7122180B2 (en) 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
JP2003012698A (ja) 2001-06-26 2003-01-15 Toyota Central Res & Dev Lab Inc モノクローナル抗体
ATE515189T1 (de) 2001-12-10 2011-07-15 California Inst Of Techn Verfahren zur herstellung von antigenspezifischen lymphozyten
US20050009180A1 (en) 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
AU2002352436B2 (en) 2001-12-18 2008-05-22 Cancer Research Technology Limited Methods for the generation of proliferating and differentiating cell lines
NZ534205A (en) 2001-12-22 2006-04-28 Antibody A 4 Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
CA2479530A1 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
MXPA05009556A (es) 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
DK1682178T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet
US7993919B2 (en) 2003-11-19 2011-08-09 The United States Of America As Represented By The Department Of Health And Human Services Method of inducing memory B cell development and terminal differentiation
GB0327384D0 (en) 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US7393923B2 (en) 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
CN101155832B (zh) 2005-02-08 2013-02-06 一般财团法人化学及血清疗法研究所 抗体的改良方法
US8337851B2 (en) 2005-05-18 2012-12-25 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer
US20090217403A1 (en) 2005-06-06 2009-08-27 Hergen Spits Means and methods for generating a t cell against an antigen of interest
EP1954811B1 (en) 2005-11-17 2011-06-08 TET Systems GmbH & Co. KG Inducible expression systems
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
EP2540820B1 (en) 2005-12-09 2018-01-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CA2757178C (en) 2009-04-03 2020-05-19 Medical Research Council Mutants of activation-induced cytidine deaminase (aid) and methods of use
CA2768207C (en) 2009-07-15 2019-12-03 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
CN102666583B (zh) 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
JP5734988B2 (ja) 2009-10-06 2015-06-17 メディミューン リミテド Ｒｓｖ特異的結合分子
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RU2585153C2 (ru) 2010-12-02 2016-05-27 Аимм Терапьютикс Б.В. Средства и способы получения высокоаффинных антител
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
WO2013109279A2 (en) 2012-01-19 2013-07-25 Therapeutic Proteins Inc. Stabilization of the anti-cd20 antibody rituximab
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos

Also Published As

Publication number Publication date
CA2938193A1 (en) 2015-09-06
JP2017504345A (ja) 2017-02-09
AU2015211480B2 (en) 2020-05-14
WO2015115892A1 (en) 2015-08-06
AU2015211480A1 (en) 2016-08-11
NZ723331A (en) 2021-08-27
EP3099709A1 (en) 2016-12-07
JP6747975B2 (ja) 2020-08-26
EP3099709B1 (en) 2019-12-25
US20170008952A1 (en) 2017-01-12
DK3099709T3 (da) 2020-02-03
CA2938193C (en) 2023-05-02
US10611829B2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
AU2019268150A1 (en) Isotyping immunoglobulins using accurate molecular mass
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112017003236A2 (pt) anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
AR101400A1 (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
MX2016012273A (es) Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union.
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
EA201400447A1 (ru) АНТИТЕЛА К CD1d
BR112017009152A2 (pt) métodos de produção de proteínas de duas cadeias em bactérias

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: AIMM THERAPEUTICS B.V. (NL)

B25A Requested transfer of rights approved

Owner name: KLING BIOTHERAPEUTICS B.V. (NL)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07K 16/00 , C07K 16/10

Ipc: C12N 5/0781 (2010.01), C07K 16/10 (2006.01), C07K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2015, OBSERVADAS AS CONDICOES LEGAIS